Prognosis of untreated hepatocellular carcinoma.

Autori: Giannini EG et al.

Data: Jan 2015

Ambito di interesse: epatologico

Rivista: Hepatology

Potrebbero interessarti anche:

Rivista 7.14

Persistent treatment resistance in genetic generalized epilepsy: A long-term outcome study in a tertiary epilepsy center

Autori: Cerulli Irelli E, Morano A, Barone FA, Fisco G, Fanella M, Orlando B, Fattouch J, Manfredi M, Giallonardo AT, Di Bonaventura C.

Data: 2020

Ambito di interesse: Epilessia

Rivista: Epilepsia. 2020 Nov;61(11):2452-2460

Leggi dettagli

Rivista

Intravenousadministration of Rituximab in the treatment of PrimaryCutaneous B-Cell Lymphomas (PCBCLs): a retrospective study

Autori:

Data: 2014

Ambito di interesse: Ematologia

Rivista: Blood (AshAnnualMetting 2014) 124 (21)

Leggi dettagli

Rivista

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Autori: Postorino M, De Santis G, Marchesi F, Provenzano I, Franceschini L, Pupo L, Rizzo M, Giannì L, Gumenyuk S, Tonialini L, Fiorelli E, Renzi D, Zizzari A.

Data: 2013

Ambito di interesse: Ematologia

Rivista: (Abstract) 12th International Congress of MalignantLymphoma, Lugano 2013. HematolOncol 2013; 31 (Suppl. 1): 201–270

Leggi dettagli

Prognosis of untreated hepatocellular carcinoma.

Potrebbero interessarti anche:

Persistent treatment resistance in genetic generalized epilepsy: A long-term outcome study in a tertiary epilepsy center

Intravenousadministration of Rituximab in the treatment of PrimaryCutaneous B-Cell Lymphomas (PCBCLs): a retrospective study

The efficacy of CHOEP chemotherapyregimenadministered in association with monoclonalantibody anti-CD52 Alemtuzumab in cutaneous T-celllymphoma (CTCL) and systemic T-celllymphoma with cutaneousinvolvement (PTCL)

Cosa fare per